Concordance between criteria for covariate model building
Authors:
- 6 March 2014
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 41 (2) , 109-125
Abstract
When performing a population pharmacokinetic modelling analysis covariates are often added to the model. Such additions are often justified by improved goodness of fit and/or decreased in unexplained (random) parameter variability. Increased goodness of fit is most commonly measured by the decrease in the objective function value. Parameter variability can be defined as the sum of unexplained (random) and explained (predictable) variability. Increase in magnitude of explained parameter variability could be another possible criterion for judging improvement in the model. The agreement between these three criteria in diagnosing covariate-parameter relationships of different strengths and nature using stochastic simulations and estimations as well as assessing covariate-parameter relationships in four previously published real data examples were explored. Total estimated parameter variability was found to vary with the number of covariates introduced on the parameter. In the simulated examples and two real examples, the parameter variability increased with increasing number of included covariates. For the other real examples parameter variability decreased or did not change systematically with the addition of covariates. The three criteria were highly correlated, with the decrease in unexplained variability being more closely associated with changes in objective function values than increases in explained parameter variability were. The often used assumption that inclusion of covariates in models only shifts unexplained parameter variability to explained parameter variability appears not to be true, which may have implications for modelling decisions.Keywords
This publication has 19 references indexed in Scilit:
- A reduction in between subject variability is not mandatory for selecting a new covariateJournal of Pharmacokinetics and Pharmacodynamics, 2012
- A Fast Method for Testing Covariates in Population PK/PD ModelsThe AAPS Journal, 2011
- Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjectsMalaria Journal, 2009
- Population pharmacokinetic and pharmacogenetic analysis of 6‐mercaptopurine in paediatric patients with acute lymphoblastic leukaemiaBritish Journal of Clinical Pharmacology, 2008
- Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patientsCancer Chemotherapy and Pharmacology, 2006
- PsN-Toolkit—A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEMComputer Methods and Programs in Biomedicine, 2005
- Models for time‐varying covariates in population pharmacokinetic‐pharmacodynamic analysisBritish Journal of Clinical Pharmacology, 2004
- Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across DrugsJournal of Clinical Oncology, 2002
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patientsJournal of Pharmacokinetics and Biopharmaceutics, 1992